Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Jakarta - Delayed Quote IDR

UBC Medical Indonesia Tbk. (LABS.JK)

Compare
114.00
0.00
(0.00%)
At close: 4:09:32 PM GMT+7
Loading Chart for LABS.JK
  • Previous Close 114.00
  • Open 114.00
  • Bid 114.00 x --
  • Ask 115.00 x --
  • Day's Range 113.00 - 115.00
  • 52 Week Range 107.00 - 228.00
  • Volume 824,000
  • Avg. Volume 1,394,973
  • Market Cap (intraday) 450.3B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

PT UBC Medical Indonesia Tbk distributes medical devices in Indonesia. It operates in two segments, Medical Disposables and Consumables, and Diagnostics and Equipment. The company offers next generation molecular, retina AI, infectious disease, HPV DNA test, real time PCR, TB management, and newborn screening products. PT UBC Medical Indonesia Tbk was founded in 2014 and is based in Jakarta Timur, Jakarta. PT UBC Medical Indonesia Tbk operates as a subsidiary of PT Optel Investama Mulia.

www.ubcindonesia.com

74

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LABS.JK

View More

Performance Overview: LABS.JK

Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is IDX COMPOSITE (^JKSE) .

YTD Return

LABS.JK
14.93%
IDX COMPOSITE (^JKSE)
9.60%

1-Year Return

LABS.JK
16.79%
IDX COMPOSITE (^JKSE)
10.67%

3-Year Return

LABS.JK
16.79%
IDX COMPOSITE (^JKSE)
11.55%

5-Year Return

LABS.JK
16.79%
IDX COMPOSITE (^JKSE)
42.84%

Compare To: LABS.JK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LABS.JK

View More

Valuation Measures

Annual
As of 4/15/2025
  • Market Cap

    450.30B

  • Enterprise Value

    450.30B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.60%

  • Return on Assets (ttm)

    2.71%

  • Return on Equity (ttm)

    4.52%

  • Revenue (ttm)

    136.7B

  • Net Income Avi to Common (ttm)

    2.19B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    43.34B

  • Total Debt/Equity (mrq)

    41.71%

  • Levered Free Cash Flow (ttm)

    -34.78B

Research Analysis: LABS.JK

View More

Company Insights: LABS.JK

Research Reports: LABS.JK

View More

People Also Watch